stockrow
Friday 6 November 2026
Export ORGO’s income statement to Excel — free account
Organogenesis
ORGO Healthcare Drug Manufacturers Specialty & Generic
Organogenesis' revenue for fiscal 2025 (year ended December 2025) was $564.2 million, up 17.0% from fiscal 2024.
- Revenue
- −69.9%
- EPS
- −327.3%
- Free cash flow
- −2,048.8%
- Total debt
- +395.3%
Quarter to September 2026, against a year earlier
0.89
0.05
+5.95%
Follow ORGO
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 4 | 5 | 4 |
+8 more TTM periods Free account |
| (81.71%) | (55.49%) | (7.68%) | 5.63% | ||
| (34.86%) | (24.40%) | (3.79%) | 2.89% | ||
ROIC |
(52.15%) | (19.97%) | 0.97% | 12.78% | |
Return on Tangible Assets |
(73.25%) | (43.23%) | (6.31%) | 4.33% | |
Average Days of Receivables |
96.10 | 80.54 | 82.90 | 140.68 | |
Free Cash Flow per Share |
0.03 | 0.16 | 0.13 | (0.19) | |
Free Cash Flow |
3.55 | 20.84 | 17.08 | (24.46) | |
Capital Expenditures |
(6.75) | (11.13) | (13.67) | (14.15) | |
| Other line items | |||||
Cash ROIC |
2.26% | 10.12% | 4.89% | (6.01%) | |
Accounts Receivable Turnover |
2.69 | 4.13 | 4.67 | 3.45 | |
Accounts Payable Turnover |
3.87 | 4.60 | 5.24 | 4.52 | |
Inventory Turnover |
3.66 | 4.35 | 4.83 | 4.93 | |
Average Days of Payables |
67.66 | 78.84 | 74.83 | 84.80 | |
Days of Inventory on Hand |
80.32 | 78.81 | 74.34 | 78.63 | |
Tax Rate |
0.58 | 1.42 | (0.36) | (0.21) | |
Research and Development Expense of Revenue |
14.69% | 12.45% | 9.53% | 7.90% | |
Selling, General and Administrative Expense of Revenue |
75.11% | 65.38% | 61.96% | 57.83% | |
Share Based Compensation of Revenue |
3.93% | 3.08% | 2.64% | 2.36% | |
Operating CF/Net income |
(0.07) | (0.30) | (1.64) | (0.65) | |
Depreciation/Fixed assets |
0.00 | 0.32 | 0.32 | 0.26 | |
Capex/Depreciation |
0.00 | (0.34) | (0.41) | (0.53) | |
Revenue per Share |
2.73 | 3.56 | 4.03 | 4.45 | |
Operating CF per Share |
0.08 | 0.25 | 0.24 | (0.08) | |
Capex per Share |
(0.05) | (0.09) | (0.11) | (0.11) | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.03 |
Columns are period end dates · fundamentals updated 5 Nov 2026